{
  "status_code": 200,
  "request": {
    "current_criteria": [
      {
        "name": "Disease",
        "type": "exclude",
        "value": "Other diseases"
      },
      {
        "name": "Disease",
        "type": "exclude",
        "value": "Early stage cancer"
      },
      {
        "name": "Population",
        "type": "exclude",
        "value": "Laboratory studies"
      },
      {
        "name": "Population",
        "type": "exclude",
        "value": "Animal studies"
      },
      {
        "name": "Population",
        "type": "exclude",
        "value": "Drug discovery studies"
      },
      {
        "name": "Outcomes",
        "type": "exclude",
        "value": "Cost and resource use in non-EU jurisdictions"
      },
      {
        "name": "Outcomes",
        "type": "exclude",
        "value": "Quality of life and health state utilities"
      },
      {
        "name": "Study methodology",
        "type": "exclude",
        "value": "Conference abstracts with little useful data"
      },
      {
        "name": "Study methodology",
        "type": "exclude",
        "value": "Narrative reviews, opinion-pieces, editorials, letters and other publications that are not primary research reports"
      },
      {
        "name": "Study size",
        "type": "exclude",
        "value": "Studies with <30 participants"
      },
      {
        "name": "Publication date",
        "type": "exclude",
        "value": "Studies published before 2015"
      },
      {
        "name": "Publication date",
        "type": "exclude",
        "value": "Conference abstracts published before 2019"
      },
      {
        "name": "Language",
        "type": "exclude",
        "value": "Full texts not in English"
      },
      {
        "name": "Disease",
        "type": "include",
        "value": "Non-small cell lung cancer"
      },
      {
        "name": "Disease",
        "type": "include",
        "value": "Colorectal cancer"
      },
      {
        "name": "Disease",
        "type": "include",
        "value": "Malignant melanoma"
      },
      {
        "name": "Disease",
        "type": "include",
        "value": "Ovarian cancer"
      },
      {
        "name": "Disease",
        "type": "include",
        "value": "Breast cancer"
      },
      {
        "name": "Disease",
        "type": "include",
        "value": "Bladder cancer"
      },
      {
        "name": "Disease",
        "type": "include",
        "value": "Cholangiocarcinoma"
      },
      {
        "name": "Disease",
        "type": "include",
        "value": "Prostate cancer"
      },
      {
        "name": "Disease",
        "type": "include",
        "value": "Thyroid cancer"
      },
      {
        "name": "Disease",
        "type": "include",
        "value": "Any cancer with one or more of the following biomarkers: MSI, TMB, NTRK, HRD/HRR, RET, ALK"
      },
      {
        "name": "Population",
        "type": "include",
        "value": "Adults or children with cancer"
      },
      {
        "name": "Interventions",
        "type": "include",
        "value": "Any relevant targeted or biomarker-directed therapy targeting the following genomic-based biomarkers (or others): ALK, ATM, BRAF, BRCA1/2, EGFR, ERBB2 gene amplification, EZH2, FGFR fusions, HRD/HRR, IDH1, KIT, KRAS/NRAS, MET, NTRK, PDGFR1, PIK3CA, RET, ROS1, SMARCB1, MSI-high, TMB-high"
      },
      {
        "name": "Interventions",
        "type": "include",
        "value": "Genomic testing of individual genes and/or genome panels"
      },
      {
        "name": "Outcomes",
        "type": "include",
        "value": "Incidence/ prevalence of cancers with targeted or genetic biomarker-directed therapies"
      },
      {
        "name": "Outcomes",
        "type": "include",
        "value": "% of patients with cancer who have genetic biomarker detected"
      },
      {
        "name": "Outcomes",
        "type": "include",
        "value": "Adoption of precision medicine:"
      },
      {
        "name": "Outcomes",
        "type": "include",
        "value": "% on-label biomarker guided treatment"
      },
      {
        "name": "Outcomes",
        "type": "include",
        "value": "% off-label biomarker guided treatment"
      },
      {
        "name": "Outcomes",
        "type": "include",
        "value": "% clinical trial eligibility or enrolment for biomarker guided investigational treatment"
      },
      {
        "name": "Outcomes",
        "type": "include",
        "value": "Survival outcomes (PFS/OS)"
      },
      {
        "name": "Outcomes",
        "type": "include",
        "value": "Response rates (complete, partial response, stable disease, disease progression, overall response, objective response rate)"
      },
      {
        "name": "Outcomes",
        "type": "include",
        "value": "Disease control rate (CR, PR or SB for \u00e2\u2030\u00a56 months)"
      },
      {
        "name": "Outcomes",
        "type": "include",
        "value": "Burden of biopsy / repeat biopsy/ tissue conservation"
      },
      {
        "name": "Outcomes",
        "type": "include",
        "value": "Time to treatment initiation"
      },
      {
        "name": "Outcomes",
        "type": "include",
        "value": "Time to treatment failure"
      },
      {
        "name": "Outcomes",
        "type": "include",
        "value": "Costs of healthcare from payer perspective (including cost of dx testing specifically)"
      },
      {
        "name": "Outcomes",
        "type": "include",
        "value": "Healthcare resource use"
      },
      {
        "name": "Outcomes",
        "type": "include",
        "value": "Operational cost of test from lab perspective"
      },
      {
        "name": "Outcomes",
        "type": "include",
        "value": "Advantages of NGS methods for genome analysis vs other methods"
      },
      {
        "name": "Study methodology",
        "type": "include",
        "value": "Clinical trials"
      },
      {
        "name": "Study methodology",
        "type": "include",
        "value": "Observational studies"
      },
      {
        "name": "Study methodology",
        "type": "include",
        "value": "Economic evaluations"
      },
      {
        "name": "Study methodology",
        "type": "include",
        "value": "Systematic reviews and meta-analysis"
      },
      {
        "name": "Study size",
        "type": "include",
        "value": "Studies with >30 participants"
      },
      {
        "name": "Publication date",
        "type": "include",
        "value": "2015 to 2021"
      },
      {
        "name": "Publication date",
        "type": "include",
        "value": "Conference abstracts: 2019 onwards"
      },
      {
        "name": "Language",
        "type": "include",
        "value": "English language only"
      }
    ],
    "conflicts": [],
    "project_description": "Comprehensive genomic profiling/NGS in solid cancers.",
    "mock": true
  },
  "response": {
    "criteria": [
      {
        "category": "Study Design",
        "text": "Exclude retrospective observational studies without a control arm",
        "description": "Conflicts frequently arose on studies lacking concurrent controls.",
        "criterion_type": "exclude",
        "confidence": 0.72,
        "rationale": "Derived from 0 reviewer conflict(s) on study design.",
        "title_abstract_assessable": true
      },
      {
        "category": "Outcome Reporting",
        "text": "Exclude studies that do not report the primary outcome quantitatively",
        "description": "Disagreements clustered around studies with narrative-only outcome reporting.",
        "criterion_type": "exclude",
        "confidence": 0.65,
        "rationale": "Pattern across 0 conflict(s) flagged insufficient outcome data.",
        "title_abstract_assessable": true
      }
    ]
  }
}